CytomX Therapeutics, Inc.

CTMXNASDAQHealthcare● Active

$2.94

$-0.06(-2.00%)

Market Cap$472821175

P/E Ratio—

52W High$8.21

52W Low$1.72

Avg Volume6.9M

Open$3.05

Beta2.09

Net Income Financials Revenue

CytomX Therapeutics, Inc. (CTMX) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CTMX · net income · updated Jun 8, 2026

Core profitability metrics

CTMX · net income · margin · TTM · CAGR

Net income was −$17.4M for FY2025 (fiscal year ending 2025-12-31), down 154.5% year-over-year. Net profit margin was -22.8%. Based on available data, CytomX Therapeutics, Inc. has been profitable since at least 2024.

FY2025 Net Income−$17.4M▼ -154.5% YoY

Trailing 12M (TTM)−$59.1Mtrailing 4 quarters sum

Net Profit Margin-22.8%−$17.4M ÷ $76.2M

YoY Change-154.5%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2024

▸ FMP /income-statement · Annual · CTMX net income history · CTMX profit margin

Annual net income data

CTMX · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$17.4M▼ 154.5%-22.8%$76.2M

FY2024★ First Profit$31.9M▲ +5700.9%23.1%$138.1M

FY2023Loss−$569,000▲ +99.4%-0.6%$101.2M

FY2022Loss−$99.3M▲ +14.3%-186.8%$53.2M

FY2021Loss−$115.9M▼ 78.8%-310.5%$37.3M

Net income vs peers (Healthcare)

CTMX vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

CytomX Therapeutics, Inc.YOU

CTMX

−$17.4M-154.5%-22.8%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

CytomX Therapeutics, Inc. (CTMX) reported net income of −$17.4M for FY2025 (fiscal year ending 2025-12-31), down 154.5% year-over-year. The net profit margin was -22.8% — meaning the company kept $-0.23 of every dollar of revenue as profit.

Based on available data, CytomX Therapeutics, Inc. has been profitable since at least 2024. Net income reached a peak of $31.9M in FY2024. Data available for 13 fiscal years.

CytomX Therapeutics, Inc.'s net profit margin was -22.8% for FY2025, based on the latest annual results.

Investors sometimes search for "CytomX Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from CTMX net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

CTMX net income · 4 questions

CytomX Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $17.4M for FY2025.

is CTMX profitabledoes CTMX make a profitCTMX profitabilityCTMX profitable company

▸ Source: FMP /income-statement · GAAP · CytomX Therapeutics, Inc. · CytomX Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026